MARLBOROUGH, Mass.,
Oct. 17, 2016 /PRNewswire/ -- Boston
Scientific Corporation (NYSE: BSX) today announced the launch of
the Resolution 360™ Clip, a novel technology designed to improve
hemostatic clipping by providing physicians controlled rotation
designed for more accurate clip placement. Boston Scientific will
introduce the clip at the annual United European Gastroenterology
Week (UEGW) in Vienna, Austria,
and at the American College of Gastroenterology annual meeting in
Las Vegas, Nevada.
Hemostatic clipping is used in a number of endoscopy procedures
of the upper and lower gastrointestinal (GI) tract to stop and help
prevent bleeding associated with conditions including peptic
ulcers, polyps removed during a colonoscopy and diverticulosis of
the colon. There are more than 240,000 incidences of GI
bleeding in the U.S. each year1 and worldwide a 10
percent mortality rate is associated with upper and lower GI
bleeds.2 A retrospective study demonstrated that
prophylactic clipping can reduce the risk of bleeding from a 9.8
percent to 1.7 percent leading to a reduction in adverse events
associated with GI bleeding.3
"The Resolution 360 Clip gives me the unique advantage of
controlling the movement and placement of the clip while also
maneuvering the scope during the clipping procedure," said
David L. Carr-Locke, MD, FRCP,
FASGE, chief, Division of Digestive Diseases, Mount Sinai Beth
Israel Medical Center, New York,
NY. "The ability to have complete control can help improve
the accuracy of clip placement and the speed of the procedure
particularly in complex cases."
The device is constructed using a multi-wire braided catheter
that is designed to enable the healthcare professional to rotate
the device in small, controlled movements in both clockwise and
counterclockwise directions, enabling the clip to be maneuvered to
the target area and more accurately placed at the site of a GI
bleed or a potential GI bleed. Physicians at the two conferences
will have the opportunity to use the Resolution 360 Clip in a
simulator to experience the device first-hand.
"We are always striving to improve our technology so that
physicians have the tools they need to diagnose and treat
gastrointestinal disease more easily and effectively," said
Art Butcher, senior vice president
and president, endoscopy. "Building on the legacy Resolution Clip
and its clinically proven technology, the expanded portfolio now
offers physicians more hemostatic clipping options to consider in
different clinical situations and patient anatomies."
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology leader
for more than 35 years, we advance science for life by providing a
broad range of high performance solutions that address unmet
patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect on Twitter
and Facebook.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements are
based on our beliefs, assumptions and estimates using information
available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements
include, among other things, statements regarding our product
launches and product performance and impact. If our underlying
assumptions turn out to be incorrect, or if certain risks or
uncertainties materialize, actual results could vary materially
from the expectations and projections expressed or implied by our
forward-looking statements. These factors, in some cases, have
affected and in the future (together with other factors) could
affect our ability to implement our business strategy and may cause
actual results to differ materially from those contemplated by the
statements expressed in this press release. As a result, readers
are cautioned not to place undue reliance on any of our
forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; the
closing and integration of acquisitions; intellectual property;
litigation; financial market conditions; and future business
decisions made by us and our competitors. All of these factors are
difficult or impossible to predict accurately and many of them are
beyond our control. For a further list and description of these and
other important risks and uncertainties that may affect our future
operations, see Part I, Item 1A – Risk Factors in our most
recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission, which we may update in Part II, Item 1A –
Risk Factors in Quarterly Reports on Form 10-Q we have filed
or will file hereafter. We disclaim any intention or obligation to
publicly update or revise any forward-looking statements to reflect
any change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.
CONTACTS
Media:
Catherine
Brady
508-683-4797
Media
Relations
Boston Scientific
Corporation
Catherine.Brady@bsci.com
Rosie Ireland
+44 (0)7585 403359
Media Relations – Europe
Boston Scientific Corporation
Rosie.Ireland@bsci.com
Investors:
Susie Lisa, CFA
508-683-5565 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com
References
- AU Loperfido S, Baldo V,Piovesana E, Bellina L, Rossi K, Gropps
M, Caroli A, Dal BóN, Monica F, Fabris L,Salvat HH, Bassi N,
Okolicsanyi L SO, Changing trends in accute upper-GI bleeding: a
population-based study. Gastrointest Endosc. 2009;70(2):212.
- Sebastian Straube; Martin R
Tramer;R. Andres Moore; Sheena Derry; Henry J. McQuay Mortality with
Upper Gastrointestinal Bleeding and Perforation: Effects of Time
and NSAID USE. BMC Gastroenterology, 2008.
- Liaquat H, Rohn E, Rex DK. "Prophylactic Clip Closure Reduced
the Risk of Delayed Postpolypectomy Hemorrhage: Experience in 277
Clipped Large Sessile or Flat Colorectal Lesions and 247 Control
Lesions." Gastrointest Endosc. 2013 Mar;77(3):401-7. doi:
10.1016/j.gie.2012.10.024. Epub 2013 Jan 11. N.p., n.d. Web.
< http://www.ncbi.nlm.nih.gov/pubmed/23317580 >.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boston-scientific-launches-resolution-360-clip-300345283.html
SOURCE Boston Scientific Corporation